Through our partnerships, Oxford BioTherapeutics has access to three of the world’s most advanced antibody technologies. We are now leveraging these agreements to generate therapeutic antibodies for the treatment of cancer



Oxford BioTherapeutics has broad access to Medarex’s UltiMAb Human Antibody Development System®. Medarex generates fully human antibodies in mice that have human gene sequences in place of the normal mouse antibody genes. Fully human antibodies are acknowledged as the next generation of antibody biologics. With Medarex, we are developing these advanced therapeutics against cancer targets that have been discovered and evaluated through our proteomics platform




Oxford BioTherapeutics diagnostics collaboration with Biosite provides provides OBT with a further source of high-quality antibodies. Biosite, a wholly-owned subsidiary of Inverness Medical Innovations, has an impressive capability in antibody development, featuring such technologies as Omniclonal® and Transphage® These systems generate very large numbers of antibodies in a high throughput manner, combining a high-affinity selection process with the rapidity and diversity of phage display technology. Oxford BioTherapeutics is thus able to obtain antibodies against our cancer targets with superior binding characteristics




Oxford BioTherapeutics has a co-development agreement with Amgen, which utilizes Xenomouse® technology to produce fully human antibodies against targets provided by Oxford BioTherapeutics. Xenomouse® adds a further source of fully human antibodies to Oxford BioTherapeutics’ top quality technology access portfolio.